U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Meta Expands AI Training With Employee Activity Tracking Tools 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
NEW YORK, March 02, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the upcoming 36th Annual Cowen & Company Global Healthcare Conference, and the 28th Annual ROTH Conference.
| 36th Annual Cowen & Company Global Healthcare Conference | |||||
| Date: | Monday, March 7 | ||||
| Time: | 3:20pm Eastern Time | ||||
| Location: | Salon C, Boston Marriott Copley Place, Boston, MA | ||||
| Webcast: | http://wsw.com/webcast/cowen30/ohrp | ||||
| 28th Annual ROTH Conference | |||||
| Date: | Tuesday, March 15 | ||||
| Time: | 3:00pm Pacific Time | ||||
| Location: | Salon 2 Blue, The Ritz Carlton Hotel, Dana Point | ||||
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. LifeSci Advisors, LLC Investor Relations Michael Wood 888-388-2327 646-597-6983 [email protected] [email protected]
